Recombinant gp120 protein with V1-loop deletion

US12162910B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• NEW YORK UNIVERSITY · US

Inventors

• Genoveffa Franchini · Washington, US
• Timothy Cardozo · New York, US
• Manuel Becerra-Flores · Brooklyn, US
• Isabela Silva de Castro · Bethesda, US
• Giacomo Gorini · Bethesda, US
• Massimiliano Bissa · Washington, US

Key dates

• Filing date: Oct 21, 2019
• Grant date: Dec 10, 2024
• Expiry date: Apr 28, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.